Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement

Shionogi said on April 25 that it has upwardly revised its earnings forecast for the year ended March 2022 thanks to the settlement of patent infringement suits over dolutegravir, an HIV drug originated by the company and GlaxoSmithKline. For FY2021,...read more